Carcinoid syndrome laboratory tests: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{Carcinoid syndrome}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Types of cancer Category:Hematology Category:Oncology [[...") |
No edit summary |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
With a certain degree of clinical suspicion, [[diagnosis]] is made primarily by measuring plasma levels of the secreted glycoprotein Chromogranin A, supported by measuring the 24 hour [[urine]] levels of [[5-HIAA]] (5-hydroxyindoleacetic acid), a breakdown product of serotonin. Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day. | |||
==References== | ==References== | ||
Revision as of 19:37, 6 August 2012
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome laboratory tests On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome laboratory tests |
|
Risk calculators and risk factors for Carcinoid syndrome laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
With a certain degree of clinical suspicion, diagnosis is made primarily by measuring plasma levels of the secreted glycoprotein Chromogranin A, supported by measuring the 24 hour urine levels of 5-HIAA (5-hydroxyindoleacetic acid), a breakdown product of serotonin. Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day.